RecruitingNot ApplicableNCT06296368

DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics

Sponsor

UNC Lineberger Comprehensive Cancer Center

Enrollment

500 participants

Start Date

Jun 21, 2024

Study Type

INTERVENTIONAL

Conditions

Multiple Myeloma Lymphoma Leukemia Hematologic Malignancies Blood Cancers

Summary

The purpose of this study is to evaluate whether a novel decision support tool called PRIME (Preference Reporting to Improve Management and Experience), which combines values-elicitation with tailored feedback to patients and providers, improves patient-reported values-concordance of initial treatment decisions compared to usual care.

Eligibility

Min Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This study evaluates a digital decision-support tool designed to help older adults who are new patients in blood cancer or bone marrow transplant clinics understand their treatment options and make informed decisions. **You may be eligible if...** - You are 60 years of age or older - You are a new patient visiting either a blood cancer clinic or a bone marrow transplant/cellular therapy clinic - You are willing and able to use a digital tool and participate in the study **You may NOT be eligible if...** - You have dementia, significant confusion, or a psychiatric condition that would prevent you from giving informed consent or participating Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALPreference Reporting to Improve Management and Experience (PRIME)

PRIME is a decision support tool that uses best-worst scaling to provide a personalized report to providers and patients of their most important treatment priorities

Locations(1)

Lineberger Comphrehensive Cancer Center at University of North Carolina

Chapel Hill, North Carolina, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06296368

Related Trials

18F-Fluciclovine PET/CT in Multiple Myeloma

NCT061038381 location

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy

NCT052379863 locations

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

NCT0617988874 locations

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

NCT054704911 location

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

NCT0458892225 locations